Ardelyx (ARDX) Income from Continuing Operations (2013 - 2026)
Ardelyx's (ARDX) quarterly Income from Continuing Operations came in at 37605000.0 in Q1 2026, up 8.6% YoY from 34626594.45 in Q1 2025, and down 9139.56% on a QoQ basis from 407000.0 in Q4 2025.
Ardelyx (ARDX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Income from Continuing Operations data on file, last reported at 37605000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 8.6% year-over-year to 37605000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58060000.0 (down 7.99% YoY) and the FY2025 annual result came in at 61599000.0, down 57.4% from the prior year.
- Income from Continuing Operations slipped to 37605000.0 in Q1 2026, from 407000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 10695000.0 in Q4 2022 to a low of 41144000.0 in Q1 2025.
- A 5-year average of 15977294.12 and a median of 19079000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 129.52% — and 2023, when it tumbled 369.3%.
- Tracing ARDX's Income from Continuing Operations over 5 years: stood at 10695000.0 in 2022, then sank by 369.3% to 28802000.0 in 2023, then soared by 116.13% to 4645000.0 in 2024, then slumped by 108.76% to 407000.0 in 2025, then slumped by 9139.56% to 37605000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 37605000.0 (Q1 2026), 407000.0 (Q4 2025), and 969000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -16.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.72 Mn |
| Mar 31, 2026 | -37.61 Mn |
| Dec 31, 2025 | -407,000.00 |
| Sep 30, 2025 | -969,000.00 |
| Jun 30, 2025 | -19.08 Mn |
| Mar 31, 2025 | -41.14 Mn |
| Dec 31, 2024 | 4.65 Mn |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | -16.45 Mn |
| Mar 31, 2024 | -26.52 Mn |
| Dec 31, 2023 | -28.80 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | -17.12 Mn |
| Mar 31, 2023 | -26.77 Mn |
| Dec 31, 2022 | 10.70 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -26.94 Mn |
| Mar 31, 2022 | -28.07 Mn |
| Dec 31, 2021 | -36.23 Mn |
| Sep 30, 2021 | -43.59 Mn |